Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Debt to Equity (2017 - 2025)

Historic Debt to Equity for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $1.34.

  • Aytu Biopharma's Debt to Equity rose 19524.61% to $1.34 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.34, marking a year-over-year increase of 19524.61%. This contributed to the annual value of $1.05 for FY2025, which is 11975.33% up from last year.
  • As of Q4 2025, Aytu Biopharma's Debt to Equity stood at $1.34, which was up 19524.61% from $1.09 recorded in Q3 2025.
  • Aytu Biopharma's 5-year Debt to Equity high stood at $1.34 for Q4 2025, and its period low was $0.11 during Q1 2021.
  • Over the past 5 years, Aytu Biopharma's median Debt to Equity value was $0.48 (recorded in 2024), while the average stood at $0.5.
  • As far as peak fluctuations go, Aytu Biopharma's Debt to Equity soared by 108498.16% in 2021, and later crashed by 766.43% in 2024.
  • Aytu Biopharma's Debt to Equity (Quarter) stood at $0.16 in 2021, then surged by 207.11% to $0.48 in 2022, then increased by 1.63% to $0.49 in 2023, then fell by 6.62% to $0.45 in 2024, then skyrocketed by 195.25% to $1.34 in 2025.
  • Its last three reported values are $1.34 in Q4 2025, $1.09 for Q3 2025, and $1.05 during Q2 2025.